Castle Biosciences Validates Enhanced DecisionDx-SCC Test Performance — Castle Biosciences, Inc.

Event summary

Castle Biosciences published a multi-center study in JAAD validating the enhanced DecisionDx-SCC test for high-risk cutaneous squamous cell carcinoma (SCC).
The integrated test (i40-GEP) combines 40-gene expression data with five clinicopathologic risk factors, improving risk stratification.
Class 1A (low risk) results showed a 97.3% negative predictive value, supporting de-escalation decisions.
Class 2B (highest risk) results identified patients with a three-year metastasis-free survival rate of 66.2%, and a 10.7x higher likelihood of metastasis than Class 1A patients.
The test outperformed traditional risk assessment systems like NCCN risk groups and BWH staging.

The big picture

Castle Biosciences' validation of the enhanced DecisionDx-SCC test underscores the growing trend toward personalized medicine in oncology. By integrating molecular data with clinicopathologic factors, the test addresses a critical gap in risk stratification for high-risk SCC patients. This development positions Castle Biosciences to capture a larger share of the dermatologic and oncologic diagnostics market, where precision medicine is increasingly becoming the standard of care.

What we're watching

Adoption Dynamics: How quickly dermatologists and oncologists integrate the enhanced DecisionDx-SCC test into clinical practice.
Competitive Positioning: Whether Castle Biosciences can maintain its lead over traditional risk assessment systems like NCCN and BWH.
Regulatory and Reimbursement: The pace at which payers recognize the test's clinical utility and provide coverage for its use.